

PRESS RELEASE

OCTOBER 18, 2021

Cerba HealthCare provides update on recent trading

The following information relating to Cerba HealthCare's recent performance is derived from our internal accounts for the months of July and August 2021. This information is based solely on preliminary internal information used by management and management estimates and remains subject to our normal end-of-quarter review process. It has not been audited, reviewed, verified or subject to any procedures by our auditors nor has it been approved by our Board of Directors, and you should not place undue reliance on it. As a result, this information may change. In particular, during the course of our review process, we could identify items that would require us to make adjustments, which might be material.

Based on preliminary internal accounts, we estimate that our net revenues for July and August 2021 amounted to approximately €256 million (of which we estimate that approximately €80 million was attributable to the impact of COVID-19, resulting in period-on-period growth, excluding the impact of COVID-19, of approximately 5%), representing growth of approximately 14% as compared to net revenues of €225 million for July and August 2020 (of which we estimate that €57 million was attributable to the impact of COVID-19). We primarily attribute this net revenue growth to sustained COVID-19 testing volume increases and continued strong performance in our core business.

We estimate that our organic like-for-like net revenue growth (including the impact of COVID-19) for July and August 2021 was approximately 12%, as compared to July and August 2020. This has been calculated based on the net revenue variation between the estimated figures for July and August 2021 as compared to July and August 2020, restated to reflect the perimeter of the Group for July and August 2021.

We estimate that for July and August 2021, our Adjusted EBITDA was approximately €77 million (of which we estimate that approximately €39 million was attributable to the impact of COVID-19, resulting in period-on-period growth, excluding the impact of COVID-19, of approximately 7%) representing growth of approximately 21% as compared to our Adjusted EBITDA of €63 million for July and August 2020 (of which we estimate that €28 million was attributable to the impact of COVID-19), with an Adjusted EBITDA margin of approximately 30% (21%, excluding the impact of COVID-19) for July and August 2021 as compared to 28% (21%, excluding the impact of COVID-19) for the prior comparable period. We primarily attribute this increase in Adjusted EBITDA to better testing management, lower subcontracted tests as a percentage of revenues and lower transportation costs. Our Adjusted EBITDA margins remain strong, driven by improved purchasing conditions and productivity gains in our core business and continued positive demand for COVID-19 testing activity.

We regularly consider opportunities to further expand our product offering and our operations in established and new geographies, as evidenced by the Lifebrain Acquisition.

Consistent with this strategy, we are advancing some bid processes and continuing negotiations to potentially acquire additional value-accretive businesses, which include one with mid-double-digit EBITDA.

Any potential acquisition would be subject to the signing of an acquisition agreement as well as customary regulatory approvals. We would expect to finance these acquisitions, if made, through a combination of debt and equity, resulting in expected broadly leverage-neutral acquisitions. There can be no assurance that such discussions will result in definitive acquisition agreements, or that such agreements would result in the consummation of an acquisition.